Acute Myeloid Leukaemia Highlights from EHA 2026: Targeted Treatments, Combination Regimens, and CAR-T Therapy

This podcast was funded by Servier.

The opinions expressed in this podcast belong solely to Sue Saville, Remco J. Molenaar, Joshua F. Zeidner, Ana Alfonso Piérola, and Alessandro Isidori.

In this podcast, moderator Sue Saville is joined by Remco J. Molenaar, Joshua F. Zeidner, Ana Alfonso Piérola, and Alessandro Isidori to discuss acute myeloid leukaemia (AML) research presented at EHA 2026. The panel reviews the role of molecular profiling in treatment selection, with particular focus on IDH1-mutated AML and findings from ALIDHE, AGILE, and studies of ivosidenib-based doublet and triplet regimens. The experts also consider venetoclax treatment duration, emerging evidence for FLT3 and menin inhibitors, the potential and challenges of CAR-T therapy in AML, and future directions for personalised treatment.

1. Independent Health Communications Specialist, UK
2. Disclosures:Consultancy and/or Advisory Boards: Servier, OncoInv
   Grants/Research Funding: Amsterdam UMC Ventures, Erasmus MC, UNIIQ, RARE-NL, Stichting Overleven Alvleesklierkanker
   Faculty:Cancer Center Amsterdam, Department of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands
3. Consultancy and/or Advisory Boards: AbbVie, Ascentage, Astellas, AstraZeneca, Aveo Pharmaceuticals, Crossbow Therapeutics, Cullinan, Daiichi Sankyo, Foghorn, Genentech, Genmab, Geron, Halia Therapeutics, Ipsen, Jazz, Johnson & Johnson, Kura Oncology, Neogenomics, Novartis, Relmada, Rigel, Sellas, Servier, Shattuck Labs, Sumitomo Pharma, Syndax
   Grants/Research Funding: AbbVie, Akeso Biopharma, Aptevo, Arog, Ascentage, AstraZeneca, Auron, Faron, Jazz, Kura Oncology, Lin Biosciences, Loxo, Novartis, Sellas, Shattuck Labs, Stemline, Sumitomo Pharma, Syndax, Zentalis
4. Honoraria from lectures: BMS, Novartis, Abbvie, Jazz Pharma, Janssen, Astellas, Otsuka, Servier
   Participation in Ad Board meetings: BMS, Syros, Jazz Pharma, Otsuka, Ascentage Pharma, Janssen, Ipsen, Abbvie, Servier
   Consultant: Astellas, Jazz Pharma; Janssen, Servier, Kyowa
   Research Founding: AstraZeneca
5. No disclosures.